Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 3
1952 1
1953 1
1961 1
1963 1
1964 1
1965 4
1966 2
1967 1
1968 1
1969 3
1972 1
1973 1
1974 1
1975 1
1976 4
1977 5
1978 6
1979 9
1980 3
1981 6
1982 4
1983 8
1984 4
1985 7
1986 6
1987 6
1988 3
1989 6
1990 13
1991 13
1992 8
1993 10
1994 14
1995 25
1996 17
1997 20
1998 17
1999 32
2000 42
2001 30
2002 33
2003 38
2004 54
2005 35
2006 50
2007 45
2008 48
2009 46
2010 47
2011 43
2012 42
2013 54
2014 69
2015 54
2016 58
2017 58
2018 47
2019 42
2020 64
2021 77
2022 83
2023 63
2024 84
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,444 results

Results by year

Filters applied: . Clear all
Page 1
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Mellinghoff IK, et al. Among authors: arakawa y. N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272516 Free PMC article. Clinical Trial.
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y. Jo U, et al. Among authors: arakawa y. Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102. doi: 10.1158/1535-7163.MCT-21-1000. Mol Cancer Ther. 2022. PMID: 35439320 Free PMC article.
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Kitagawa J, Aoi A, Nishikawa R. Narita Y, et al. Among authors: arakawa y. Neuro Oncol. 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145. Neuro Oncol. 2021. PMID: 32583848 Free PMC article. Clinical Trial.
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients.
Hangai M, Kawaguchi T, Takagi M, Matsuo K, Jeon S, Chiang CWK, Dewan AT, De Smith AJ, Imamura T, Okamoto Y, Saito AM, Deguchi T, Kubo M, Tanaka Y, Ayukawa Y, Hori T, Ohki K, Kiyokawa N, Inukai T, Arakawa Y, Mori M, Hasegawa D, Tomizawa D, Fukushima H, Yuza Y, Noguchi Y, Taneyama Y, Ota S, Goto H, Yanagimachi M, Keino D, Koike K, Toyama D, Nakazawa Y, Nakamura K, Moriwaki K, Sekinaka Y, Morita D, Hirabayashi S, Hosoya Y, Yoshimoto Y, Yoshihara H, Ozawa M, Kobayashi S, Morisaki N, Gyeltshen T, Takahashi O, Okada Y, Matsuda M, Tanaka T, Inazawa J, Takita J, Ishida Y, Ohara A, Metayer C, Wiemels JL, Ma X, Mizutani S, Koh K, Momozawa Y, Horibe K, Matsuda F, Kato M, Manabe A, Urayama KY. Hangai M, et al. Among authors: arakawa y. Haematologica. 2024 Apr 1;109(4):1247-1252. doi: 10.3324/haematol.2023.282914. Haematologica. 2024. PMID: 37881853 Free PMC article. No abstract available.
Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Arakawa Y, Jo U, Kumar S, Sun NY, Elloumi F, Thomas A, Roper N, Varghese DG, Takebe N, Zhang X, Ceribelli M, Holland DO, Beck E, Itkin Z, McKnight C, Wilson KM, Travers J, Klumpp-Thomas C, Thomas CJ, Hoang CD, Hernandez JM, Del Rivero J, Pommier Y. Arakawa Y, et al. Cancer Res Commun. 2024 Mar 19;4(3):834-848. doi: 10.1158/2767-9764.CRC-24-0085. Cancer Res Commun. 2024. PMID: 38451783 Free PMC article.
[Liver abscess].
Arakawa Y, Amaki S, Moriyama M, Tanaka N. Arakawa Y, et al. Ryoikibetsu Shokogun Shirizu. 1999;(23 Pt 1):442-5. Ryoikibetsu Shokogun Shirizu. 1999. PMID: 10088439 Review. Japanese. No abstract available.
Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study.
Higo H, Ichikawa H, Arakawa Y, Mori Y, Itano J, Taniguchi A, Senoo S, Kimura G, Tanimoto Y, Miyake K, Katsuta T, Kataoka M, Maeda Y, Kiura K, Miyahara N, Okayama Respiratory Disease Study Group Ordsg. Higo H, et al. Among authors: arakawa y. J Clin Med. 2023 Aug 9;12(16):5174. doi: 10.3390/jcm12165174. J Clin Med. 2023. PMID: 37629217 Free PMC article.
Daptomycin Susceptibility of Group B Streptococcus.
Ushino T, Jin W, Wachino JI, Arakawa Y, Kimura K. Ushino T, et al. Among authors: arakawa y. Jpn J Infect Dis. 2021 May 24;74(3):233-235. doi: 10.7883/yoken.JJID.2020.371. Epub 2020 Sep 30. Jpn J Infect Dis. 2021. PMID: 32999183 Free article.
1,444 results